Herpes simplex virus 2 (HSV-2) infections are common throughout the world. HSV-2 is
the most common pathogen of genital herpes. As there are no curative therapies which
can effectively control the recurrence of HSV infection, development of an effective
and safe vaccine against HSV has become a hot point of research [
[1]
]. It has been demonstrated that gD can induce significant cellular and humoral immune
responses resulting in the protection of animals from lethal HSV infection [
[2]
]. However, none was therapeutically effective and most were poorly immunogenic in
human clinical trials [
[3]
]. The general failure of prior vaccines suggests the need to test other viral vaccine,
particularly those capable of eliciting CD8+ T cell responses. A successful therapeutic vaccine may require different antigens
and adjuvants than previously tried [
[3]
]. It has been well known that Hsps have adjuvant effect in peptide immunization to
initiate specific cellular immune responses against associated antigens [
[4]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Role of mucosal immunity in preventing genital herpes infection.Viral Immunol. 2005; 18: 595-609
- Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.Vaccine. 2004; 23: 236-246
- Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.Herpes. 2004; 11: 161A-169A
- Defective CD8 T cell memory following acute infection without CD4 T cell help.Science. 2003; 300: 339-342
- DNA vaccines: immunology, application, and optimization.Annu Rev Immunol. 2000; 18: 927-974
- Peptide-based cancer vaccines.Semin Oncol. 2002; 9: 494-520
- Prediction and clone of T cell epitope region of HSV-2 gD protein.Chin J Derm Venereol. 2007; 21: 330-333
- CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.Immunity. 2001; 14: 303-313
- Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules.J Biol Chem. 2001; 276: 17163-17171
- IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.J Immunol. 1999; 162: 2912-2921
Article info
Publication history
Published online: July 12, 2010
Accepted:
October 27,
2009
Received in revised form:
October 21,
2009
Received:
September 10,
2008
Identification
Copyright
© 2009 Japanese Society for Investigative Dermatology. Published by Elsevier Inc. All rights reserved.
